Supernus Pharmaceuticals SUPN Business Segments — Total revenues
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's business segments — total revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's business segments — total revenues?
- Supernus Pharmaceuticals (SUPN) reported business segments — total revenues of $207.71M in Q1 2026.
- How has Supernus Pharmaceuticals's business segments — total revenues changed year-over-year?
- Supernus Pharmaceuticals's business segments — total revenues increased by 38.6% year-over-year, from $149.82M to $207.71M.
- What is the long-term trend for Supernus Pharmaceuticals's business segments — total revenues?
- Over 3 years (2022 to 2025), Supernus Pharmaceuticals's business segments — total revenues has grown at a 2.5% compound annual growth rate (CAGR), from $667.24M to $718.95M.
- What does business segments — total revenues mean?
- Represents the total gross income generated by the company's primary business segment from the sale of pharmaceutical products. This metric serves as the top-line indicator of market demand and commercial success for the company's neuroscience portfolio.